AstraZeneca Q3 Results Highlight Oncology-Led Momentum
AstraZeneca Q3 results showed stronger revenue and core EPS and cited late-stage readouts and approvals on Oct. 30, 2026, refining investor positioning.
KEY TAKEAWAYS
- Q3 revenue was $16.2 billion, up 7.0% year over year.
- Core EPS rose to $2.79, up 17.0% at actual exchange rates.
- Management reaffirmed 2026 guidance for mid-to-high single-digit revenue growth and low double-digit core EPS growth.
HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX
Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.
AstraZeneca’s Q3 results on Oct. 30, 2026, showed sustained commercial momentum that supported revenue and profit growth. The company cited late-stage clinical readouts and regulatory approvals as the foundation for future sales prospects.
Quarterly Results and Guidance
For the quarter ended Sept. 30, 2026, AstraZeneca reported revenue of $16.2 billion, up 7.0% year over year at actual and constant exchange rates. Core earnings per share (EPS) rose 17.0% at actual exchange rates to $2.79 and 19.0% at constant exchange rates. Reported EPS increased 23.0% at actual exchange rates to $2.02.
For the nine months ended Sept. 30, 2026, revenue reached $46.9 billion, up 8.0% at actual exchange rates and 7.0% at constant exchange rates. Core EPS for the period rose 14.0% to $8.00, while core operating profit increased 14.0% at constant exchange rates to $16.4 billion.
Product sales for the quarter totaled $15.1 billion, up 5.0% at actual and constant exchange rates. Alliance revenue grew 36.0% to $1.1 billion, boosting overall top-line and earnings performance.
AstraZeneca reaffirmed its 2026 guidance for mid-to-high single-digit percentage total-revenue growth and low double-digit core EPS growth at constant exchange rates. The company scheduled an investor and analyst conference call for 14:30 UK time, attributing ongoing growth to commercial momentum across therapy areas and progress in its development pipeline.
Pipeline and Commercial Drivers
AstraZeneca said double-digit growth in oncology, respiratory and immunology, and rare disease offset headwinds from loss of exclusivity for Farxiga and Brilinta and volume-based procurement in China. Management highlighted this therapy-area mix as a key buffer against generic competition and pricing pressures.
Since its Q4 2025 results, the company has secured 47 approvals in major regions, including first approvals for four new medicines—Etcamah, Baxfendy, Klygefa, and Amlypave—expanding its marketed portfolio across multiple indications.
The company reported 12 positive Phase III program readouts during 2026 through the nine-month period. It said these late-stage successes have collective peak-year revenue potential well above $10 billion, signaling significant midterm commercial opportunity.
AstraZeneca plans to publish its fourth-quarter and full-year 2026 results on Feb. 9, 2027.
